At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 176 enrolled
Drug / intervention
Tiotropium +2 moredrug
Likely dose
Tiotropium 18mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects With COPD
In Brief
A Phase 2 clinical trial evaluating Tiotropium, Placebo, and 1 other intervention for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 176 participants across 19 sites in 2 countries.
Detailed Summary
The study will evaluate the dose response, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesGermany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartSep 2009
Primary CompletionMar 2010
Study CompletionMar 2010
TodayJul 2026
First PostedAug 3, 2009
Enrollment StartSep 1, 2009
Primary CompletionMar 1, 2010
Study CompletionMar 15, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.9 years ago
Interventions
Tiotropiumdrug
long-acting muscarinic receptor antagonist; 18mcg once-daily
Placebodrug
Inactive/ excipients only
GSK573179drug
GSK573179 investigational drug